Cytomegalovirus-induced Colon Perforation in Systemic Lupus Erythematosus

To the Editor:

Acute abdomen has been reported in 10% of patients with systemic lupus erythematosus (SLE). The differential diagnoses of abdominal pain in SLE do not differ significantly from those in patients without SLE with the exception of serositis, thrombotic, or hemorrhagic events associated with antiphospholipid antibodies, mesenteric vasculitis (MV), and cytomegalovirus (CMV) infection. The distinction between MV and CMV infection is critical because both are life-threatening disorders requiring radically different therapeutic approaches. We describe the case of a patient with SLE who was profoundly immunosuppressed and who presented with an acute surgical abdomen secondary to a colonic perforation, and emphasize the relevance of considering a viral etiology in this setting.

A 54-year-old woman with a 22-year history of SLE presented to the Emergency Department with acute abdominal pain. Previous manifestations of her disease included serositis, arthritis, nephritis, and cytopenias. In 2001, the patient received induction (cyclophosphamide) and maintenance [azathioprine (AZA)] therapy for class IV lupus nephritis (National Institutes of Health criteria activity index 5, chronicity index 8). Optimization of the AZA dose was limited because of myelosuppression. Over the previous 8 months, her creatinine had increased progressively from a baseline of 200 mmol/l to 350 mmol/l. A month prior to the current admission, the patient had a preemptive renal transplant evaluation. At the time, prednisone (50 mg/day) was added to her chronic immunosuppressive therapy (AZA 50 mg/day).

On admission, the patient had excruciating, stabbing, and diffuse abdominal pain. She denied having nausea, vomiting, dysphagia, diarrhea, melena, weight loss, urinary symptoms, or fever. On examination, her abdomen was rigid and diffusely tender, with guarding in all quadrants and rebound tenderness. Results of laboratory tests included leukocytes 1.8 × 10⁹/l, absolute lymphocytes 0.10 × 10⁹/l, hemoglobin 11.7 g/dl, platelets 139 × 10⁹/l, alanine aminotransferase 64 U/l, aspartate aminotransferase 48 U/l, alkaline phosphatase 88 U/l (normal 42–98), amylase 442 U/l (normal 20–130), lipase 65 U/l (normal 14–45), creatinine 433 umol/l, complement fraction 3 (C3) 0.77 g/l (normal 0.79–1.52), and C4 0.33 g/l (normal 0.16–0.38). Antinuclear antibody was positive (1:160) with a speckled pattern, while anti-DNA, anti-SM, Ro/La, anticardiolipin antibodies, and lupus anticoagulant were all negative. The SLE Disease Activity Index (SLEDAI) score was 4. An abdominal computed tomography (CT) scan showed free air in the upper retroperitoneal area with an inflammatory focus adjacent to the splenic flexure (Figure 1). A perforation of the distal transverse colon/splenic flexure was diagnosed, for which she underwent resection with end colostomy. On histology, a transmural ulceration of the colon without evidence of vasculitis was found. CMV inclusions were documented adjacent to the perforation by immunohistochemistry (Figure 2). CMV viral load (quantitative PCR) was 1.63 × 10⁴ copies/ml. Following the diagnosis of CMV gastrointestinal (GI) disease, ophthalmology confirmed the presence of lesions close to retinal vessels consistent with CMV-associated retinitis. AZA was discontinued and ganciclovir was initiated (70 mg intravenous, 3 times weekly). The postoperative course was complicated by venous thrombosis of the right basilic and right peroneal veins, an event that has been associated with CMV infection.

Differential diagnoses of life-threatening abdominal complications in SLE include lupus MV, intestinal pseudo-obstruction, and generalized megaviscera, acute pancreatitis (secondary to SLE or drug-related, i.e., AZA), protein-losing gastroenteropathy, and other less common entities (i.e., eosinophilic enteritis, pneumatosis cystoides intestinalis).

MV is the most commonly reported cause of bowel perforation in SLE. MV is a life-threatening disorder with an associated mortality of up to 50%. It occurs in patients with high disease activity (SLEDAI > 8) and usually manifests with insidious diffuse abdominal pain that may be intermittent for months prior to the development of an acute abdomen. The presence of cutaneous vasculitis, central nervous system involvement, thrombocytopenia, lymphopenia, and rheumatoid factor positivity in a patient with SLE with an acute abdomen suggest the diagnosis of MV.

Common but nonspecific CT findings in patients with MV include dilated bowel, focal or diffuse bowel wall thickening/enhancement (double halo or target sign), mesenteric edema, engorgement of mesenteric vessels (comb sign), and ascites. Involvement of the duodenum was reported to be highly suggestive of vasculitis.

Overt CMV clinical disease in SLE is rare and is associated with high mortality rates. The risk of CMV infection is higher in patients treated with cyclophosphamide or combined immunosuppressive agents (i.e., AZA/mycophenolate acid and glucocorticoids). Other risk factors associated with life-threatening viral infections in SLE include renal insufficiency, antiphospholipid syndrome, and delayed onset of antiviral therapy. CMV involvement of the GI tract usually manifests as single or multiple ulcerations (“punched out” appearance) and GI bleeding. Colonic perforation because of CMV infection is exceedingly rare.

The diagnosis of CMV GI disease relies upon culture and histopathology of a tissue biopsy. Although

![Figure 1. Abdominal computed tomography (coronal image): inflammatory focus adjacent to the splenic colonic flexure (arrow).](www.jrheum.org)
the value of CMV DNA tests to establish symptomatic infection in patients with SLE has not been established, the level of CMV load and its rate of increase predict symptomatic disease in transplant patients. Coexisting manifestations such as pneumonitis and/or retinitis should suggest the diagnosis of tissue-invasive CMV disease.

This case emphasizes the challenges of the differential diagnosis between MV and CMV GI involvement in a patient presenting with a colonic perforation. It is of utmost clinical importance to include viral infections as a differential diagnosis in patients with immunosuppressed SLE presenting with an acute abdomen. Performing early serological and molecular studies will confirm diagnosis and guide life-saving therapy.

TETIANA GLUSHKO, MD, Division of Rheumatology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada; VICTORIA A. MARCUS, MD FRCP, Associate Professor, Department of Pathology, McGill University Health Centre, Montreal, Quebec, Canada; INÉS COLMEGNA, MD, Assistant Professor, Division of Rheumatology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada. Address correspondence to Dr. I. Colmegna, Division of Rheumatology, Department of Medicine, McGill University Health Centre, Royal Victoria Hospital, 1001 Décarie Blvd., Bloc E, M2-3238, Montréal, Québec H4A 3J1, Canada. E-mail: ines.colmegna@mcgill.ca

REFERENCES